Estatísticas Básicas
| CIK | 1631487 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to CollPlant Biotechnologies Ltd.
SEC Filings (Chronological Order)
Esta página fornece uma lista completa e cronológica de Arquivamentos da SEC, excluindo os arquivamentos de propriedade que fornecemos em outro lugar.
| May 29, 2026 |
COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Exhibit 99.1 COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE REHOVOT, Israel, May 29, 2026 - CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and medical aesthetics company developing innovative technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen) for tissue regeneration and medical aesthetics |
|
| May 29, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2026 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| April 21, 2026 |
PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-294738 3,296,000 Ordinary Shares This prospectus relates to the resale, by the selling shareholders identified in this prospectus, of up to an aggregate of 3,296,000 ordinary shares, par value NIS 1.50 per share of CollPlant Biotechnologies Ltd., consisting of (i) 1,600,000 ordinary shares issuable upon the exercise of series A warra |
|
| April 17, 2026 |
CollPlant Biotechnologies Ltd. 4 Oppenheimer, Weizmann Science Park Rehovot 7670104, Israel April 17, 2026 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: CollPlant Biotechnologies Ltd. Registration Statement on Form F-1 File No. 333-294738 VIA EDGAR Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amen |
|
| April 15, 2026 |
As filed with the Securities and Exchange Commission on April 15, 2026 As filed with the Securities and Exchange Commission on April 15, 2026 Registration No. |
|
| April 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2026 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| April 13, 2026 |
Exhibit 99.1 Letter to Shareholders Collaborations As noted, Allergan Industrie SAS, an AbbVie company, notified us that it was exercising its right to terminate the development agreement, previously entered into in February 2021 , upon 60 days’ advance notice . During the prior five years, AbbVie was developing a dermal and soft tissue filler product for commercialization in the medical aesthetic |
|
| April 1, 2026 |
April 1, 2026 Yehiel Tal Chief Executive Officer CollPlant Biotechnologies Ltd. 4 Oppenheimer, Weizmann Science Park Rehovot 7670104, Israel Re: CollPlant Biotechnologies Ltd. Registration Statement on Form F-1 Filed March 30, 2026 File No. 333-294738 Dear Yehiel Tal: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 |
|
| March 30, 2026 |
As filed with the Securities and Exchange Commission on March 30, 2026 As filed with the Securities and Exchange Commission on March 30, 2026 Registration No. |
|
| March 30, 2026 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES F-1 CollPlant Biotechnologies Ltd Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Ordinary shares, par value NIS 1. |
|
| March 26, 2026 |
CERTIFICATION OF THE CHIEF FINANCIAL OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT Exhibit 12.2 CERTIFICATION OF THE CHIEF FINANCIAL OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT I, Eran Rotem, certify that: 1. I have reviewed this annual report on Form 20-F of CollPlant Biotechnologies Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the |
|
| March 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2026 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| March 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report For the transition period from to Commission File No. |
|
| March 26, 2026 |
CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT Exhibit 12.1 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT I, Yehiel Tal, certify that: 1. I have reviewed this annual report on Form 20-F of CollPlant Biotechnologies Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the |
|
| March 26, 2026 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 Kost Forer Gabbay & Kasierer 144 Menachem Begin Road, Building A Tel-Aviv 6492102, Israel Tel: +972-3-6232525 Fax: +972-3-5622555 ey.com CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statements (Form F-3 Nos. 333-238731, 333-269087 and 333-292640) of CollPlant Biotechnolo |
|
| March 26, 2026 |
CERTIFICATION OF CHIEF FINANCIAL OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Exhibit 13.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of CollPlant Biotechnologies Ltd. (the “Company”) hereby certifies to such officer’s knowledge that: (i) the accompanying Annual Report on Form 20-F of the Company for the year ende |
|
| March 26, 2026 |
CERTIFICATION OF CHIEF EXECUTIVE OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Exhibit 13.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of CollPlant Biotechnologies Ltd. (the “Company”) hereby certifies to such officer’s knowledge that: (i) the accompanying Annual Report on Form 20-F of the Company for the year ende |
|
| March 26, 2026 |
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Exhibit 99.1 COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE REHOVOT, Israel, March 26, 2026 - CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived rhCollagen for tissue regeneration and medical aesthetics, today announced its 2025 financial res |
|
| March 24, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2026 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| March 24, 2026 |
CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement Exhibit 99.1 CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement REHOVOT, Israel, March 24, 2026 /PRNewswire/ - CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen) platform, today announced that on March 23, 2026, |
|
| February 26, 2026 |
Exhibit 99.1 CollPlant Biotechnologies Announces Korean Patent Allowance Secured for its Photocurable Dermal Filler ● Intellectual Property Rights Secured in One of the Largest Target Markets for CollPlant's Product Candidate REHOVOT, Israel, February 26, 2026 /PRNewswire/ - CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies a |
|
| February 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2026 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| February 23, 2026 |
CollPlant Elevates rhCollagen 3D Bioprinting Portfolio with Launch of Ready-to-Print BioFlex Exhibit 99.1 CollPlant Elevates rhCollagen 3D Bioprinting Portfolio with Launch of Ready-to-Print BioFlex · BioFlex Enables Rapid Formulation of Tunable rhCollagen Bioinks with Enhanced Tissue-Mimetic Performance · BioFlex Expands CollPlant’s Animal-Free Bioink Platform for Biopharma companies and Academic institutions Seeking Superior Biofunctionality and Reproducibility REHOVOT, Israel, February |
|
| February 23, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2026 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| February 17, 2026 |
Exhibit 99.1 CollPlant Targets New Aesthetic Market Driven by GLP-1 Weight-Loss Treatments Next-generation rhCollagen-based technology aims to restore facial structure and skin quality in patients experiencing volume depletion linked to GLP-1 weight-loss therapies REHOVOT, Israel February 17 2026 - CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing i |
|
| February 17, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2026 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| February 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2026 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| February 6, 2026 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-292640 PROSPECTUS SUPPLEMENT (To prospectus dated January 16, 2026) 1,600,000 Ordinary Shares We are offering 1,600,000 of our ordinary shares, par value NIS 1.50 per share, or the ordinary shares, to certain institutional investors pursuant to this prospectus supplement and accompanying prospectus. The purchase price of each ordinary share is |
|
| February 6, 2026 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 4, 2026, between CollPlant Biotechnologies Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). |
|
| February 6, 2026 |
[SERIES A/SERIES B] ORDINARY SHARE PURCHASE WARRANT CollPlant Biotechnologies Ltd. Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| February 6, 2026 |
PLACEMENT AGENT ORDINARY SHARE PURCHASE WARRANT CollPlant Biotechnologies Ltd. Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| February 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2026 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| January 9, 2026 |
As filed with the Securities and Exchange Commission on January 9, 2026 As filed with the Securities and Exchange Commission on January 9, 2026 Registration No. |
|
| January 9, 2026 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES F-3 CollPlant Biotechnologies Ltd Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid Equity Ordinary Shares, par value NIS 1. |
|
| December 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2025 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| November 26, 2025 |
Notice to Owners of Ordinary Shares CollPlant Biotechnologies Ltd. Proxy/Voting Card Exhibit 99.2 Notice to Owners of Ordinary Shares CollPlant Biotechnologies Ltd. Proxy/Voting Card Owners of record by the close of business on December 1, 2025 (the “Record Date”) of ordinary shares of CollPlant Biotechnologies Ltd. (the “Company”) are hereby notified of an upcoming annual and extraordinary general meeting of the Company to be held on December 31, 2025 at 10:00 a.m. Israel time in |
|
| November 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2025 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| November 26, 2025 |
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Exhibit 99.1 COLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE ● Expansion of rhCollagen and BioInk raw material sales in North American territories expected through a new partnership with a U.S.-based logistics center scheduled to become operational this quarter and under new commercial leadership for this region ● Recent developments suggest Col |
|
| November 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2025 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| November 26, 2025 |
Exhibit 99.1 CollPlant Biotechnologies Ltd. 4 Oppenheimer St, Weizmann Science Park Rehovot 7670104, Israel NOTICE OF ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To be held on Wednesday, December 31, 2025 The annual and extraordinary general meeting of shareholders of CollPlant Biotechnologies Ltd. (the “Company”) will be held at the offices of Goldfarb Gross Seligman & Co. at One Azr |
|
| October 27, 2025 |
Exhibit 99.1 CollPlant Expands its rhCollagen Distribution Capabilities in the United States and Canada - New North American logistics center will provide expanded distribution for CollPlant’s rhCollagen and BioInks as well as enable logistical efficiencies - REHOVOT, Israel, October 27, 2025 – CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innov |
|
| October 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2025 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| October 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2025 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| October 20, 2025 |
Exhibit 99.1 CollPlant’s rhCollagen-Based BioInk Demonstrates Strong Performance Compared to Matrigel® in Study Conducted by Technion – Israel Institute of Technology ● A head-to-head study by Israel’s Technion found that CollPlant’s rhCollagen-based bioink, Collink.3D™, outperformed Matrigel®, a leading extracellular matrix, in supporting structured tissue formation. ● The findings suggest Collin |
|
| October 16, 2025 |
Exhibit 99.1 First-in-Kind Fully Humanized 3D Bioprinted Human Skin Model Developed by Mayo Clinic Researchers using CollPlant's rhCollagen-Based BioInk ● The bioprinted skin model is designed to serve as an alternative to animal testing for preclinical research. ● According to a scientific article published in the Archives of Dermatological Research, the model developed by Mayo Clinic researchers |
|
| October 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2025 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| October 9, 2025 |
144 0001740791 XXXXXXXX LIVE 0001631487 CollPlant Biotechnologies Ltd 001-38370 4 Oppenheimer St. |
|
| September 30, 2025 |
Exhibit 99.1 CollPlant Biotechnologies Announces Positive Results from non-clinical Studies of its Photocurable Regenerative Dermal and Soft Tissue Filler CollPlant is now moving towards clinical trials and scaling and optimizing its manufacturing to ensure readiness for the upcoming clinical trials REHOVOT, Israel September 30, 2025 - CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and a |
|
| September 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| September 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| September 15, 2025 |
CollPlant Expands the Distribution of its VergenixSTR Product in Europe Exhibit 99.1 CollPlant Expands the Distribution of its VergenixSTR Product in Europe REHOVOT, Israel, September 15, 2025 – CollPlant Biotechnologies (Nasdaq: CLGN), or “CollPlant”, a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced the expansion of it |
|
| September 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| August 28, 2025 |
X0101 EFFECT 33 LIVE 2025-08-28 0001213900-25-078973 POS AM 0001631487 CollPlant Biotechnologies Ltd 333-288109 |
|
| August 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| August 20, 2025 |
Exhibit 99.2 COLLPLANT BIOTECHNOLOGIES LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) AS OF JUNE 30, 2025 TABLE OF CONTENTS Page CONDENSED CONSOLIDATED FINANCIAL STATEMENTS: Condensed Consolidated Balance Sheets F-2 - F-3 Condensed Consolidated Statements of Operations F-4 Condensed Consolidated Statements of Shareholder’s Equity F-5 - F-6 Condensed Consolidated Statements of Cash Fl |
|
| August 20, 2025 |
OPERATING AND FINANCIAL REVIEW AND PROSPECTS Exhibit 99.3 OPERATING AND FINANCIAL REVIEW AND PROSPECTS The following discussion and analysis should be read in conjunction with our consolidated financial statements and related notes included elsewhere in this Form 6-K and our Annual Report on Form 20-F for the year ended December 31, 2024 (the “Annual Report”). Unless the context requires otherwise, the terms “CollPlant,” “we,” “us,” “our,” “ |
|
| August 20, 2025 |
Exhibit 99.1 COLLPLANT BIOTECHNOLOGIES REPORTS 2025 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Preparing to initiate clinical studies for photocurable dermal filler with production scale-up underway - - Raised $3.6 million in registered direct offering in second quarter - REHOVOT, Israel, August 20, 2025 – CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic |
|
| August 20, 2025 |
As filed with the Securities and Exchange Commission on August 20, 2025 As filed with the Securities and Exchange Commission on August 20, 2025 Registration No. |
|
| July 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| July 14, 2025 |
Exhibit 99.1 CollPlant Appoints Collagen Biomaterials Expert as New Head of North America Commercial Operations New U.S.-based role to support growth strategy, partnerships, and scaling of rhCollagen product platforms REHOVOT, Israel – July 14, 2025 – CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing disruptive technologies and products based on it |
|
| July 3, 2025 |
PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-288109 1,272,002 Ordinary Shares This prospectus relates to the resale, by the selling shareholders identified in this prospectus, of up to an aggregate of 1,272,002 ordinary shares, par value NIS 1.50 per share of CollPlant Biotechnologies Ltd., consisting of (i) 1,200,002 ordinary shares issuable upon the exercise of warrants origi |
|
| July 1, 2025 |
CollPlant Biotechnologies Ltd. 4 Oppenheimer, Weizmann Science Park Rehovot 7670104, Israel July 1, 2025 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: CollPlant Biotechnologies Ltd. Registration Statement on Form F-1 File No. 333-288109 VIA EDGAR Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amende |
|
| June 30, 2025 |
June 30, 2025 Yehiel Tal Chief Executive Officer CollPlant Biotechnologies Ltd 4 Oppenheimer, Weizmann Science Park Rehovot 7670104, Israel Re: CollPlant Biotechnologies Ltd Registration Statement on Form F-1 Filed June 17, 2025 File No. |
|
| June 17, 2025 |
As filed with the Securities and Exchange Commission on June 17, 2025 As filed with the Securities and Exchange Commission on June 17, 2025 Registration No. |
|
| June 17, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form F-1 (Form Type) CollPlant Biotechnologies Ltd. |
|
| June 9, 2025 |
Exhibit 99.1 COLLPLANT BROADENS ITS COLLABORATION WITH STEMCELL TECHNOLOGIES CollPlant’s proprietary rhCollagen to be used in clinical and commercial applications REHOVOT, Israel, June 9, 2025 - CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its plant-derived, Type I recombinant human collagen (rhCol |
|
| June 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| June 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| June 4, 2025 |
Exhibit 99.1 COLLPLANT BIOTECHNOLOGIES ANNOUNCES EUROPEAN PATENT ALLOWANCE SECURED FOR ITS COLLAGEN-BASED FORMULATIONS USABLE AS SOFT TISSUE FILLERS AND IMPLANTS - Further protection granted in key territory applying to the significant and growing aesthetic and reconstructive markets - REHOVOT, Israel, June 4, 2025 - CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine |
|
| June 2, 2025 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-269087 PROSPECTUS SUPPLEMENT (To prospectus dated January 10, 2023) 1,200,002 Ordinary Shares We are offering 1,200,002 of our ordinary shares par value NIS 1.50 per share, to certain institutional investors pursuant to this prospectus supplement and accompanying prospectus. The purchase price of each ordinary share is $3.00. In a concurrent pr |
|
| June 2, 2025 |
PLACEMENT AGENT ORDINARY SHARE PURCHASE WARRANT CollPlant Biotechnologies Ltd. Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| June 2, 2025 |
ORDINARY SHARE PURCHASE WARRANT CollPlant Biotechnologies Ltd. Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| June 2, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement") is dated as of May 29, 2025, between CollPlant Biotechnologies Ltd., a company organized under the laws of the State of Israel (the “Company"), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers"). WHER |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| May 30, 2025 |
Exhibit 99.1 COLLPLANT BIOTECHNOLOGIES ANNOUNCES $3.6 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES REHOVOT, Israel, May 30, 2025 — CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today anno |
|
| May 28, 2025 |
Exhibit 99.1 COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE - In Q1 following a development achievement, CollPlant received a $2 million payment from AbbVie – - Advancement of regenerative breast implant program continues; encouraging findings continue to be observed - REHOVOT, Israel, May 28, 2025 – CollPlant Biotechnologies (Nasdaq: CLGN), |
|
| May 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| April 15, 2025 |
Exhibit 99.1 CollPlant’s Collink.3D® BioInks and Technologies Offer a Relevant and Timely Solution to FDA’s Plan to Reduce Animal Testing in Preclinical Safety Studies CollPlant’s novel rhCollagen BioInks are an available solution aligned with FDA’s plan announced last week to phase out the animal testing requirement for the development of monoclonal antibody therapies and other drug candidates RE |
|
| March 26, 2025 |
CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT Exhibit 12.1 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT I, Yehiel Tal, certify that: 1. I have reviewed this annual report on Form 20-F of CollPlant Biotechnologies Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the |
|
| March 26, 2025 |
COLLPLANT BIOTECHNOLOGIES LTD. INSIDER TRADING POLICY Exhibit 11.1 COLLPLANT BIOTECHNOLOGIES LTD. INSIDER TRADING POLICY This Insider Trading Policy (the “Policy”) sets forth the policy for directors, officers and employees, of Collplant Biotechnologies Ltd. and its subsidiaries (the “Company”) with respect to transactions in the Company’s securities or securities of certain other publicly traded companies while in possession of confidential informat |
|
| March 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| March 26, 2025 |
DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT Exhibit 2.1 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT General The authorized and registered share capital of CollPlant Biotechnologies Ltd. (the “Company”) is NIS 45,000,000 divided into 30,000,000 ordinary shares, nominal (par) value NIS 1.50 each. The Nasdaq Global Market Our ordinary shares are listed on The Nasdaq Capital Market under the symbol “CLGN”. Memorand |
|
| March 26, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 Kost Forer Gabbay & Kasierer 144 Menachem Begin Road, Building A Tel-Aviv 6492102, Israel Tel: +972-3-6232525 Fax: +972-3-5622555 ey.com CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statements (Form F-3 No. 333-238731 and 333-269087) of CollPlant Biotechnologies Ltd., an |
|
| March 26, 2025 |
CERTIFICATION OF THE CHIEF FINANCIAL OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT Exhibit 12.2 CERTIFICATION OF THE CHIEF FINANCIAL OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT I, Eran Rotem, certify that: 1. I have reviewed this annual report on Form 20-F of CollPlant Biotechnologies Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the |
|
| March 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report For the transition period from to Commission File No. |
|
| March 26, 2025 |
CERTIFICATION OF CHIEF FINANCIAL OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Exhibit 13.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of CollPlant Biotechnologies Ltd. (the “Company”) hereby certifies to such officer’s knowledge that: (i) the accompanying Annual Report on Form 20-F of the Company for the year ende |
|
| March 26, 2025 |
Exhibit 99.1 COLLPLANT BIOTECHNOLOGIES REPORTS 2024 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE CollPlant announces six-month study data from its regenerative breast implant program, which could provide a revolutionary alternative to women for aesthetic or medical purposes and aims to address a $3 billion market opportunity Recently received a $2 million development payment from AbbVie Confe |
|
| March 26, 2025 |
CERTIFICATION OF CHIEF EXECUTIVE OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Exhibit 13.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of CollPlant Biotechnologies Ltd. (the “Company”) hereby certifies to such officer’s knowledge that: (i) the accompanying Annual Report on Form 20-F of the Company for the year ende |
|
| February 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| February 24, 2025 |
CollPlant Expands Distribution for its VergenixSTR Product in Europe and Asia Exhibit 99.1 CollPlant Expands Distribution for its VergenixSTR Product in Europe and Asia REHOVOT, Israel, February 24, 2025 – CollPlant Biotechnologies (Nasdaq: CLGN), or “CollPlant”, a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced the expansion |
|
| February 12, 2025 |
Exhibit 99.1 CollPlant Biotechnologies Provides a Corporate Update - Additional patent granted for photocurable dermal filler - Update on AbbVie dermal filler program and achievement of contingent payment - Plan for cost reductions in place to extend cash runway REHOVOT, Israel, February 12, 2025 – CollPlant Biotechnologies (Nasdaq: CLGN), or “CollPlant”, a regenerative and aesthetics medicine com |
|
| February 12, 2025 |
Exhibit 99.2 CollPlant Corporate Presentation Nasdaq : CLGN February 2025 The statements made in this presentation speak only as of the date stated herein, and subsequent events and developments may cause our expectations and beliefs to change. Unless otherwise required by applicable securities laws, we do not intend, nor do we undertake any obligation, to update or revise any forward - looking st |
|
| February 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| January 28, 2025 |
EX-99.A 2 tm254488d1ex99-a.htm EXHIBIT A CUSIP No. 19516R107 Page 1 of 2 EXHIBIT A JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Ordinary Shares, par value NIS 1.5 per share |
|
| November 27, 2024 |
Exhibit 99.1 COLLPLANT BIOTECHNOLOGIES REPORTS 2024 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE -Promising results obtained from the pre-clinical study with CollPlant’s commercial sized rhCollagen-based regenerative breast implants, demonstrating significant implant vascularization and rapid ingrowth of native tissue -Innovative breast implant technology designed to address a $3. |
|
| November 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| September 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| August 20, 2024 |
Exhibit 99.1 COLLPLANT BIOTECHNOLOGIES REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE -Recently initiated a pre-clinical trial with CollPlant’s rhCollagen-based regenerative breast implants, printed with Stratasys’ Origin® 3D printer that are 200cc in volume -Breast implants could address a $3.0 billion market opportunity – -Cash and cash equivalents balance as of June |
|
| August 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| August 20, 2024 |
OPERATING AND FINANCIAL REVIEW AND PROSPECTS Exhibit 99.3 OPERATING AND FINANCIAL REVIEW AND PROSPECTS The following discussion and analysis should be read in conjunction with our consolidated financial statements and related notes included elsewhere in this Form 6-K and our Annual Report on Form 20-F for the year ended December 31, 2023 (the “Annual Report”). Unless the context requires otherwise, the terms “CollPlant,” “we,” “us,” “our,” “ |
|
| August 20, 2024 |
Notice to Owners of Ordinary Shares CollPlant Biotechnologies Ltd. Proxy/Voting Card Exhibit 99.2 Notice to Owners of Ordinary Shares CollPlant Biotechnologies Ltd. Proxy/Voting Card Owners of record by the close of business on August 26, 2024 (the “Record Date”) of ordinary shares of CollPlant Biotechnologies Ltd. (the “Company”) are hereby notified of an upcoming annual and extraordinary general meeting of the Company to be held on September 25, 2024 in Israel (the “Meeting”). S |
|
| August 20, 2024 |
Exhibit 99.2 COLLPLANT BIOTECHNOLOGIES LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) AS OF JUNE 30, 2024 TABLE OF CONTENTS Page CONDENSED CONSOLIDATED FINANCIAL STATEMENTS: Condensed Consolidated Balance Sheets F-2 - F-3 Condensed Consolidated Statements of Operations F-4 Condensed Consolidated Statements of Shareholder’s Equity F-5 - F-6 Condensed Consolidated Statements of Cash Fl |
|
| August 20, 2024 |
Exhibit 99.1 CollPlant Biotechnologies Ltd. 4 Oppenheimer St, Weizmann Science Park Rehovot 7670104, Israel NOTICE OF ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To be held on Tuesday, September 25, 2024 The annual and extraordinary general meeting of shareholders of CollPlant Biotechnologies Ltd. (the “Company”) will be held at the offices of Goldfarb Gross Seligman & Co. at One Azri |
|
| August 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| August 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| August 19, 2024 |
Exhibit 99.1 News Release CollPlant and Stratasys Announce Pre-clinical Study for Regenerative Commercial-Sized Breast Implants 3D Printed Breast implants consisting of 200cc in volume of CollPlant’s rhCollagen- based bioinks produced on a Stratasys’ Origin® printer to be tested Technology innovation addresses a $3.0 billion market opportunity Study to focus on ability of implants to grow natural |
|
| July 29, 2024 |
CollPlant Biotechnologies Unveils Inaugural ESG and Sustainability Report Exhibit 99.1 CollPlant Biotechnologies Unveils Inaugural ESG and Sustainability Report REHOVOT, Israel, July 29, 2024 - CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced the release of its inaugural Environme |
|
| July 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| June 6, 2024 |
Exhibit 99.1 CollPlant Successfully Bio-Prints 200cc Commercial-Size Regenerative Breast Implants and Reports Additional Positive Pre-Clinical Data - Bio-printing technology now enables fabrication of 200cc implant size and above to address future commercial demand. - Interim pre-clinical data shows tissue growth including regeneration of maturing connective tissue as well as neovascularization, s |
|
| June 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| May 29, 2024 |
As filed with the Securities and Exchange Commission on May 29, 2024 As filed with the Securities and Exchange Commission on May 29, 2024 Registration No. |
|
| May 29, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) CollPlant Biotechnologies Ltd. |
|
| May 29, 2024 |
Exhibit 99.1 CollPlant Biotechnologies Announces First Quarter Financial Results For 2024 and Provides Corporate Update Additional large-animal study with commercial-size breast implants commenced in December 2023 expected to conclude in June 2024 Cash and cash equivalents balance as of March 31, 2024, was $23.2 million Conference call and webcast to discuss its financial results and corporate upd |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| April 4, 2024 |
Exhibit 4.4 COLLPLANT BIOTECHNOLOGIES LTD. 2024 SHARE AWARD PLAN COLLPLANT BIOTECHNOLOGIES LTD. 2024 SHARE AWARD PLAN 1. Purposes of the Plan. The purpose of this 2024 Share Award Plan (the “Plan”) is to advance the interests of CollPlant Biotechnologies Ltd. (the “Company”) and its shareholders by attracting and retaining the best available personnel for positions of substantial responsibility, p |
|
| April 4, 2024 |
CERTIFICATION OF THE CHIEF FINANCIAL OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT Exhibit 12.2 CERTIFICATION OF THE CHIEF FINANCIAL OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT I, Eran Rotem, certify that: 1. I have reviewed this annual report on Form 20-F of CollPlant Biotechnologies Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the |
|
| April 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| April 4, 2024 |
Tel: +972-3-6232525 Fax: +972-3-5622555 Exhibit 15.1 Kost Forer Gabbay & Kasierer 144 Menachem Begin Road, Building A Tel-Aviv 6492102, Israel Tel: +972-3-6232525 Fax: +972-3-5622555 ey.com CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statements (Form F-3 No. 333-238731 and 333-269087) of CollPlant Biotechnologies Ltd., an |
|
| April 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report For the transition period from to Commission File No. |
|
| April 4, 2024 |
COLLPLANT HOLDINGS LTD. (the “Company”) SHARE OWNERSHIP AND OPTION PLAN (2010) TABLE OF CONTENTS Exhibit 4.3 COLLPLANT HOLDINGS LTD. (the “Company”) SHARE OWNERSHIP AND OPTION PLAN (2010) TABLE OF CONTENTS 1. Preamble. 1 2. Administration of the Plan. 2 3. Shares Subject to the Plan. 2 4. Option Exercise Prices. 3 5. Exclusivity of the Plan. 3 6. Grant of the Options and Issuance of the Shares to the Trustee. 3 7. Option or Share Purchase Agreement; Termination of Employment. 5 8. Assumption |
|
| April 4, 2024 |
CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT Exhibit 12.1 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT I, Yehiel Tal, certify that: 1. I have reviewed this annual report on Form 20-F of CollPlant Biotechnologies Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the |
|
| April 4, 2024 |
Exhibit 99.1 COLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Dermal filler program with AbbVie in clinical phase - Regenerative breast implant program large-animal study underway to evaluate commercial-size implants with topline data expected in Q4 - Ends 2023 with $26.7 million in cash and cash equivalents - Conference call to be held on Thursday |
|
| April 4, 2024 |
CERTIFICATION OF CHIEF FINANCIAL OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Exhibit 13.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of CollPlant Biotechnologies Ltd. (the “Company”) hereby certifies to such officer’s knowledge that: (i) the accompanying Annual Report on Form 20-F of the Company for the year ende |
|
| April 4, 2024 |
CERTIFICATION OF CHIEF EXECUTIVE OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Exhibit 13.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of CollPlant Biotechnologies Ltd. (the “Company”) hereby certifies to such officer’s knowledge that: (i) the accompanying Annual Report on Form 20-F of the Company for the year ende |
|
| February 15, 2024 |
Exhibit 99.1 CollPlant Issues Letter to Shareholders Rehovot, Israel, February 15, 2024 – CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, is pleased to issue the following letter from its Chief Executive Officer, Yehiel T |
|
| February 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| February 13, 2024 |
SC 13G/A 1 clgna121324.htm JAMES C. ROUMELL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* CollPlant Biotechnologies Ltd. (Name of Issuer) Ordinary shares, par value NIS 1.50 per share (Title of Class of Securities) M2R51X116 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of th |
|
| January 25, 2024 |
IL:CLGN / Collplant Biotechnologies Ltd / Loewenbaum Lilian S. - SC 13G/A Passive Investment SC 13G/A 1 tm244103-1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* CollPlant Biotechnologies Ltd. (Name of Issuer) Ordinary Shares, par value NIS 1.5 per share (including Ordinary Shares represented by American Depositary Shares (ADSs) at a ratio of one Ordinary Share per each AD |
|
| January 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| January 2, 2024 |
Exhibit 99.1 CollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants ● The current market for breast implants is estimated at $2.6 billion a year ● CollPlant expects the study to conclude by the first half of 2024 ● CollPlant plans to use findings from this study and successive studies during 2024 for further optimization of the implant design towards |
|
| November 29, 2023 |
CollPlant Biotechnologies Announces Third Quarter Financial Results for 2023 Exhibit 99.1 CollPlant Biotechnologies Announces Third Quarter Financial Results for 2023 ● Received a $10 million milestone payment in the third quarter from partner, AbbVie Inc., for achieving a major milestone in the second quarter in accordance with the strategic collaboration agreement related to the clinical-phase dermal filler product candidate ● Company is preparing to launch large-animal |
|
| November 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| November 1, 2023 |
Exhibit 99.1 CollPlant Biotechnologies Announces Patent Granted in U.S. for Photocurable Dermal Filler - Intellectual Property Rights Secured in One of the Largest Target Markets for CollPlant’s Potential Products - REHOVOT, Israel, November 1, 2023, CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its |
|
| October 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| September 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| September 21, 2023 |
Exhibit 99.1 CollPlant Biotechnologies Joins the United Nations Global Compact, The World’s Largest Corporate Sustainability Initiative - As a new participant, the Company strengthens its commitment to operate sustainably and transition the regenerative and aesthetics medicine industry to sustainable alternatives - REHOVOT, Israel, September 21, 2023, CollPlant Biotechnologies (NASDAQ: CLGN), a re |
|
| September 1, 2023 |
Notice to Owners of Ordinary Shares CollPlant Biotechnologies Ltd. Proxy/Voting Card Exhibit 99.2 Notice to Owners of Ordinary Shares CollPlant Biotechnologies Ltd. Proxy/Voting Card Owners of record on September 7, 2023 (the “Record Date”) of ordinary shares of CollPlant Biotechnologies Ltd. (the “Company”) are hereby notified of an upcoming extraordinary general meeting of the Company to be held on October 10, 2023 in Israel (the “Meeting”). Shareholders registered in the Compan |
|
| September 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| September 1, 2023 |
Exhibit 99.1 CollPlant Biotechnologies Ltd. 4 Oppenheimer St, Weizmann Science Park Rehovot 7670104, Israel NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To be held on Tuesday, October 10, 2023 The extraordinary general meeting of shareholders of CollPlant Biotechnologies Ltd. (the “Company”) will be held at the offices of Goldfarb Gross Seligman & Co. at One Azrieli Center, Round Buildi |
|
| August 24, 2023 |
OPERATING AND FINANCIAL REVIEW AND PROSPECTS Exhibit 99.3 OPERATING AND FINANCIAL REVIEW AND PROSPECTS The following discussion and analysis should be read in conjunction with our consolidated financial statements and related notes included elsewhere in this Form 6-K and our Annual Report on Form 20-F for the year ended December 31, 2022 (the “Annual Report”). Unless the context requires otherwise, the terms “CollPlant,” “we,” “us,” “our,” “ |
|
| August 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| August 24, 2023 |
Exhibit 99.1 CollPlant Biotechnologies Announces Second Quarter Financial Results For 2023 with Revenues of $10.2 Million ● Received in July 2023, $10 million from partner, AbbVie, for achieving a major milestone in the second quarter, for the clinical-phase dermal filler product in accordance with the strategic collaboration agreement ● Entered into collaboration with Stratasys, a world-leading 3 |
|
| August 24, 2023 |
Exhibit 99.2 COLLPLANT BIOTECHNOLOGIES LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) AS OF JUNE 30, 2023 COLLPLANT BIOTECHNOLOGIES LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) AS OF JUNE 30, 2023 TABLE OF CONTENTS Page CONDENSED CONSOLIDATED FINANCIAL STATEMENTS: Condensed Consolidated Balance Sheets F-2 - F-3 Condensed Statements of Operations F-4 Condensed Consolid |
|
| July 24, 2023 |
CLGN / CollPlant Biotechnologies Ltd New / MEITAV DASH INVESTMENTS LTD - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 6)* CollPlant Biotechnologies Ltd (Name of Issuer) Ordinary Shares, par value NIS 0.03 per share (Title of Class of Securities) 19516Q208 (CUSIP Number) July 20, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| July 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| June 26, 2023 |
Exhibit 99.1 CollPlant Achieves Milestone and To Receive $10 Million From AbbVie in Accordance with its Regenerative Dermal Filler Product Collaboration Agreement REHOVOT, Israel, June 26, 2023 – CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration an |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| June 8, 2023 |
Exhibit 99.1 CollPlant Biotechnologies Ltd. 4 Oppenheimer St, Weizmann Science Park Rehovot 7670104, Israel NOTICE OF ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To be held on Tuesday, July 18, 2023 The annual and extraordinary general meeting of shareholders of CollPlant Biotechnologies Ltd. (the “Company”) will be held at the offices of Goldfarb Gross Seligman & Co. at One Azrieli C |
|
| June 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| June 8, 2023 |
Notice to Owners of Ordinary Shares CollPlant Biotechnologies Ltd. Proxy/Voting Card Exhibit 99.2 Notice to Owners of Ordinary Shares CollPlant Biotechnologies Ltd. Proxy/Voting Card Owners of record on June 15, 2023 (the “Record Date”) of ordinary shares of CollPlant Biotechnologies Ltd. (the “Company”) are hereby notified of an upcoming annual and extraordinary general meeting of the Company to be held on July 18, 2023 in Israel (the “Meeting”). Shareholders registered in the Co |
|
| May 24, 2023 |
Exhibit 99.1 CollPlant Biotechnologies Announces First Quarter Financial Results For 2023 and Provides Corporate Update ● Strong positive sales trajectory for rhCollagen based products ● Continued advancement of strategic collaboration with AbbVie to develop dermal and soft tissue filler products using CollPlant’s recombinant human Collagen ● Readying sites to begin large-animal study planned in t |
|
| May 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| April 18, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) CollPlant Biotechnologies Ltd. |
|
| April 18, 2023 |
As filed with the Securities and Exchange Commission on April 18, 2023 As filed with the Securities and Exchange Commission on April 18, 2023 Registration No. |
|
| April 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| April 11, 2023 |
Exhibit 99.1 1 APRIL 202 3 NASDAQ: CLGN Company Overview Our Mission Developing and delivering collagen technology and regenerative medicine products to improve and prolong lives 2 Certain statements in this presentation constitute "forward - looking statements" within the meaning of Section 27 A of the Securities Act and Section 21 E of the Securities Exchange Act and are usually identified by th |
|
| April 4, 2023 |
Exhibit 99.1 News Release Stratasys and CollPlant Unite Technologies to Transform Healthcare with Industrial-Scale Bioprinting of Tissues and Organs Joint development and commercialization agreement will initially focus on development of bioprinting solution for CollPlant’s regenerative breast implants, addressing $2.6 billion market opportunity Stratasys’ P3 technology-based bioprinter and CollPl |
|
| April 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report For the transition period from to Commission File No. |
|
| March 29, 2023 |
Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statements (Form F-3 No. 333-228054, 333-238731, and 333-269087) of CollPlant Biotechnologies Ltd., and in the related Prospectuses, and (2) Registration Statements (Form S-8 No. 333-229163, 333-248479 and 333-263842) pertaini |
|
| March 29, 2023 |
Certification of the Chief Financial Officer pursuant to 18 U.S.C. 1350 Exhibit 13.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of CollPlant Biotechnologies Ltd. (the “Company”) hereby certifies to such officer’s knowledge that: (i) the accompanying Annual Report on Form 20-F of the Company for the year ende |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| March 29, 2023 |
Exhibit 12.1 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT I, Yehiel Tal, certify that: 1. I have reviewed this annual report on Form 20-F of CollPlant Biotechnologies Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the |
|
| March 29, 2023 |
Certification of the Chief Executive Officer pursuant to 18 U.S.C. 1350 Exhibit 13.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of CollPlant Biotechnologies Ltd. (the “Company”) hereby certifies to such officer’s knowledge that: (i) the accompanying Annual Report on Form 20-F of the Company for the year ende |
|
| March 29, 2023 |
Exhibit 12.2 CERTIFICATION OF THE CHIEF FINANCIAL OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT I, Eran Rotem, certify that: 1. I have reviewed this annual report on Form 20-F of CollPlant Biotechnologies Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the |
|
| March 29, 2023 |
Description of Securities Registered under Section 12. Exhibit 2.1 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT General The authorized and registered share capital of CollPlant Biotechnologies Ltd. (the “Company”) is NIS 45,000,000 divided into 30,000,000 ordinary shares, nominal (par) value NIS 1.50 each. The Nasdaq Global Market Our ordinary shares are listed on The Nasdaq Capital Market under the symbol “CLGN”. Memorand |
|
| March 29, 2023 |
Exhibit 99.1 Collplant Biotechnologies Announces Full-Year Financial Results For 2022 and Provides Corporate Update ● Continued advancement of strategic collaboration with AbbVie to develop dermal and soft tissue filler products using CollPlant's recombinant human (rh)Collagen ● Additional large-animal study planned in H2 2023 to further 3D bioprinted regenerative breast implant program ● Conferen |
|
| February 13, 2023 |
SC 13G 1 clgn21323.htm JAMES C. ROUMELL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 CollPlant Biotechnologies Ltd. (Name of Issuer) Ordinary shares, par value NIS 1.50 per share (Title of Class of Securities) M2R51X116 (CUSIP Number) February 13, 2023 (Date of Event which Requires Filing of this Statement) Check the |
|
| January 30, 2023 |
IL:CLGN / Collplant Biotechnologies Ltd / INVESTMENT MANAGEMENT OF VIRGINIA LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* COLLPLANT BIOTECHNOLOGIES LTD. M2R51X116 December 31, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ X ] Rule 13d-1 (b) [ ] Rule 13d-1 (c) [ ] Rule 13d-1 (d) *The remainder of this cover page shall be fil |
|
| January 25, 2023 |
IL:CLGN / Collplant Biotechnologies Ltd / Loewenbaum Lilian S. - SC 13G/A Passive Investment SC 13G/A 1 tm234354d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* CollPlant Biotechnologies Ltd. (Name of Issuer) Ordinary Shares, par value NIS 1.5 per share (including Ordinary Shares represented by American Depositary Shares (ADSs) at a ratio of one Ordinary Share per each AD |
|
| January 24, 2023 |
Exhibit 99.1 CollPlant Issues Letter to Shareholders REHOVOT, Israel, January 24, 2023 /PRNewswire/ - CollPlant (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, is pleased to issue the following letter from its Chief Executive Officer, Yehiel Tal, to its shareholders Dear shareholders, As |
|
| January 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| January 11, 2023 |
CLGN / CollPlant Holdings, Ltd. / MEITAV DASH INVESTMENTS LTD - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5)* CollPlant Biotechnologies Ltd (Name of Issuer) Ordinary Shares, par value NIS 0.03 per share (Title of Class of Securities) 19516Q208 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| January 11, 2023 |
EX-99 2 exhibit1.htm EXHIBIT 1 Exhibit 1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Ordinary Shares, par value NIS 0.03 per share of CollPlant Biotechnologie |
|
| January 9, 2023 |
CollPlant Biotechnologies Ltd. 4 Oppenheimer, Weizmann Science Park Rehovot 7670104, Israel January 9, 2023 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: CollPlant Biotechnologies Ltd. Registration Statement on Form F-3 File No. 333-269087 VIA EDGAR Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as ame |
|
| January 6, 2023 |
United States securities and exchange commission logo January 6, 2023 Yehiel Tal Chief Executive Officer CollPlant Biotechnologies Ltd 4 Oppenheimer, Weizmann Science Park Rehovot 7670104, Israel Re: CollPlant Biotechnologies Ltd Registration Statement on Form F-3 Filed December 30, 2022 File No. |
|
| January 6, 2023 |
Collplant Biotechnologies Ltd. 4 Oppenheimer St. Weizmann Science Park Rehovot 7670104 Collplant Biotechnologies Ltd. 4 Oppenheimer St. Weizmann Science Park Rehovot 7670104 Israel January 6, 2023 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-7010 Re: Collplant Biotechnologies Ltd. Registration Statement on Form F-3 File No. 333-269087 VIA EDGAR Ladies and Gentlemen: Reference is made to the Registration Statement on For |
|
| January 4, 2023 |
Exhibit 99.1 CollPlant Announces Successful Pre-Clinical Results in 3D Bioprinted Regenerative Breast Implants Porcine Study and Full Achievement of Objectives ? Study demonstrated progressive stages of tissue regeneration as highlighted by the formation of maturing connective tissue and neovascular networks within the implants ? No indication of adverse reaction was noted ? Promising results supp |
|
| January 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| January 3, 2023 |
Exhibit 99.1 CollPlant Enriches Portfolio of rhCollagen-Based Bioinks with Launch of Collink.3DTM 50L in Powder Form ? Company?s first bioink available in powder form provides enhanced operational flexibility to support a wide range of 3D bioprinting applications ? Collink.3D? 50L strengthens CollPlant?s platform of bioink solutions to biopharma and academic customers seeking animal-free alternati |
|
| January 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| December 30, 2022 |
As filed with the Securities and Exchange Commission on December 30, 2022 As filed with the Securities and Exchange Commission on December 30, 2022 Registration No. |
|
| December 30, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form F-3 (Form Type) CollPlant Biotechnologies Ltd (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Ordinary Shares, par value NIS 1. |
|
| December 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| December 1, 2022 |
CollPlant Biotechnologies Provides Business Updates and Third Quarter 2022 Financial Results Exhibit 99.1 CollPlant Biotechnologies Provides Business Updates and Third Quarter 2022 Financial Results ? Partnership with AbbVie to co-develop rhCollagen-based dermal and soft tissue fillers continues to advance according to plan ? Co-developing 3D bioprinted human intestine model (?Gut-on-a-Chip?) for drug discovery and personalized treatment of ulcerative colitis with Tel-Aviv University and |
|
| November 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| November 17, 2022 |
Exhibit 99.1 CollPlant Overview November 2022 Safe harbor statement Certain statements in this presentation constitute "forward - looking statements" within the meaning of Section 27 A of the Securities Act and Section 21 E of the Securities Exchange Act and are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," |
|
| November 15, 2022 |
Exhibit 99.1 CollPlant, Tel Aviv University and Sheba Medical Center Join Forces to Co-Develop rhCollagen-Based 3D Bioprinted Human Intestine Model for Drug Discovery and Personalized Treatment of Ulcerative Colitis ● Agreement to accelerate development of a “Gut-on-a-Chip” tissue model to improve therapeutic choice and outcome of ulcerative colitis patients ● CollPlant to fund development and rec |
|
| November 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| November 7, 2022 |
CollPlant Expands rhCollagen-Based Bioink Platform with Launch of Collink.3D 90 Exhibit 99.1 CollPlant Expands rhCollagen-Based Bioink Platform with Launch of Collink.3D 90 ? Collink.3DTM 90 offers additional functionality to address wide range of 3D bioprinting applications, including soft and hard tissues ? Collink.3DTM 90 demonstrates faster human cell migration into gel matrices compared with a commercial hydrogel widely used for 2D and 3D cell culture ? Second bioink lau |
|
| August 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| August 26, 2022 |
Exhibit 99.1 CollPlant Overview August 2022 Safe harbor statement Certain statements in this presentation constitute "forward - looking statements" within the meaning of Section 27 A of the Securities Act and Section 21 E of the Securities Exchange Act and are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "s |
|
| August 25, 2022 |
OPERATING AND FINANCIAL REVIEW AND PROSPECTS Exhibit 99.3 OPERATING AND FINANCIAL REVIEW AND PROSPECTS The following discussion and analysis should be read in conjunction with our consolidated financial statements and related notes included elsewhere in this Form 6-K and our Annual Report on Form 20-F for the year ended December 31, 2021 (the ?Annual Report?). Unless the context requires otherwise, the terms ?CollPlant,? ?we,? ?us,? ?our,? ? |
|
| August 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| August 25, 2022 |
Exhibit 99.2 COLLPLANT BIOTECHNOLOGIES LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) AS OF JUNE 30, 2022 COLLPLANT BIOTECHNOLOGIES LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) AS OF JUNE 30, 2022 TABLE OF CONTENTS Page CONDENSED CONSOLIDATED FINANCIAL STATEMENTS: Condensed Consolidated Balance Sheets F-2 - F-3 Condensed Consolidated Statements of Comprehensive Income |
|
| August 25, 2022 |
CollPlant Biotechnologies Provides Business Updates and Second Quarter 2022 Financial Results Exhibit 99.1 CollPlant Biotechnologies Provides Business Updates and Second Quarter 2022 Financial Results ? Co-development of rhCollagen-based dermal and soft tissue fillers with AbbVie is progressing ? Company?s 3D bioprinted regenerative breast implant program remains on track to conclude large animal study in Q4 ? Development of aseptic process for the production of sterile rhCollagen anticipa |
|
| June 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| June 29, 2022 |
CollPlant Advances its 3D Bioprinted Regenerative Breast Implants into Porcine Study Exhibit 99.1 CollPlant Advances its 3D Bioprinted Regenerative Breast Implants into Porcine Study ? rhCollagen-based regenerative breast implants address $2.8 billion global breast implant market with revolutionary and potentially safer new product ? Regenerative breast implants for aesthetic and reconstructive procedures including postmastectomy for cancer patients ? The study is planned to be co |
|
| May 26, 2022 |
CollPlant Biotechnologies Provides Business Updates and First Quarter 2022 Financial Results Exhibit 99.1 CollPlant Biotechnologies Provides Business Updates and First Quarter 2022 Financial Results ? Co-development of rhCollagen-based dermal and soft tissue filler products with AbbVie is advancing according to plan ? Launch of large animal study for Company?s 3D bioprinted regenerative breast implant program is on track for Q2 2022 ? Initiate development of a 3D bioprinted tissue model o |
|
| May 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| May 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| April 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2022 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| April 14, 2022 |
Exhibit 99.1 CollPlant Overview April 2022 Safe harbor statement Certain statements in this presentation constitute "forward - looking statements" within the meaning of Section 27 A of the Securities Act and Section 21 E of the Securities Exchange Act and are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "se |
|
| March 25, 2022 |
As filed with the Securities and Exchange Commission on March 25, 2022 As filed with the Securities and Exchange Commission on March 25, 2022 Registration No. |
|
| March 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2022 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| March 25, 2022 |
EX-FILING FEES 4 ea157363ex107collplant.htm FILING FEE TABLE Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) CollPlant Biotechnologies Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fe |
|
| March 25, 2022 |
Notice to Owners of Ordinary Shares CollPlant Biotechnologies Ltd. Proxy/Voting Card Exhibit 99.2 Notice to Owners of Ordinary Shares CollPlant Biotechnologies Ltd. Proxy/Voting Card Owners of record on April 4, 2022 (the ?Record Date?) of ordinary shares of CollPlant Biotechnologies Ltd. (the ?Company?) are hereby notified of an upcoming annual and extraordinary general meeting of the Company to be held on May 2, 2022 in Israel (the ?Meeting?). Shareholders registered in the Comp |
|
| March 25, 2022 |
Exhibit 99.1 CollPlant Biotechnologies Ltd. 4 Oppenheimer St, Weizmann Science Park Rehovot 7670104, Israel NOTICE OF ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To be held on Monday, May 2, 2022 The annual and extraordinary general meeting of shareholders of CollPlant Biotechnologies Ltd. (the ?Company?) will be held at the offices of Gross & Co. at One Azrieli Center, Round Building |
|
| March 24, 2022 |
Certification of the Chief Financial Officer pursuant to 18 U.S.C. 1350 Exhibit 13.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of CollPlant Biotechnologies Ltd. (the “Company”) hereby certifies to such officer’s knowledge that: (i) the accompanying Annual Report on Form 20-F of the Company for the year ende |
|
| March 24, 2022 |
Certification of the Chief Executive Officer pursuant to 18 U.S.C. 1350 Exhibit 13.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of CollPlant Biotechnologies Ltd. (the “Company”) hereby certifies to such officer’s knowledge that: (i) the accompanying Annual Report on Form 20-F of the Company for the year ende |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report For the transition period from to Commission File No. |
|
| March 24, 2022 |
Exhibit 15.2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (Nos. 333-228054 and 333-238731) and on Form S-8 (Nos. 333-229163 and 333-248479) of CollPlant Biotechnologies Ltd. of our report dated April 1, 2020 relating to the financial statements, which appears in this Form 20-F. Tel-Aviv, Isra |
|
| March 24, 2022 |
Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statements (Form S-8 No. 333-229163 and 333-248479) pertaining to the Employees' Savings Plan of CollPlant Biotechnologies Ltd., and to the incorporation by reference in the Registration Statement (Form F-3 No. 333-228054 and 333-238731) of CollPlant Biotechnologie |
|
| March 24, 2022 |
Exhibit 12.2 CERTIFICATION OF THE CHIEF FINANCIAL OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT I, Eran Rotem, certify that: 1. I have reviewed this annual report on Form 20-F of CollPlant Biotechnologies Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the |
|
| March 24, 2022 |
Exhibit 12.1 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT I, Yehiel Tal, certify that: 1. I have reviewed this annual report on Form 20-F of CollPlant Biotechnologies Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the |
|
| March 24, 2022 |
CollPlant Biotechnologies Provides Business Updates and Fiscal Year 2021 Financial Results Exhibit 99.1 CollPlant Biotechnologies Provides Business Updates and Fiscal Year 2021 Financial Results ? Record revenues in 2021 of $15.6 million versus $6.1 million in 2020 ? Continued progress of strategic agreement with AbbVie to develop dermal and soft tissue filler products using CollPlant's rhCollagen ? Company to advance 3D bioprinted regenerative breast implant program with launch of larg |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2022 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| February 24, 2022 |
IL:CLGN / Collplant Biotechnologies Ltd / Hargrove Reginald J. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* CollPlant Biotechnologies Ltd. (Name of Issuer) Ordinary Shares, par value NIS 1.5 per share (including Ordinary Shares represented by American Depositary Shares (ADSs) at a ratio of one Ordinary Share per each ADS) (Title of Class of Securities) 19516R |
|
| February 23, 2022 |
IL:CLGN / Collplant Biotechnologies Ltd / Loewenbaum Lilian S. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* CollPlant Biotechnologies Ltd. (Name of Issuer) Ordinary Shares, par value NIS 1.5 per share (including Ordinary Shares represented by American Depositary Shares (ADSs) at a ratio of one Ordinary Share per each ADS) (Title of Class of Securities) 19516R1 |
|
| February 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2022 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| February 16, 2022 |
Exhibit 99.1 CELLINK and CollPlant Enter a Collaboration Agreement to Explore Future Large-Scale Production of CollPlant's Regenerative Breast Implants using CELLINK's Bioprinting technologies CollPlant and CELLINK will explore the use of CELLINK's next-generation high throughput extrusion bioprinters for the future commercial production of CollPlant's regenerative breast implants, addressing a $2 |
|
| February 2, 2022 |
Agreement of Joint Filing by and among the Reporting Persons, dated as of December 31, 2021. Exhibit 1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Ordinary Shares, par value NIS 0. |
|
| February 2, 2022 |
CLGN / CollPlant Holdings, Ltd. / MEITAV DASH INVESTMENTS LTD - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4)* CollPlant Biotechnologies Ltd (Name of Issuer) Ordinary Shares, par value NIS 0.03 per share (Title of Class of Securities) 19516Q208 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| January 31, 2022 |
IL:CLGN / Collplant Biotechnologies Ltd / INVESTMENT MANAGEMENT OF VIRGINIA LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* COLLPLANT BIOTECHNOLOGIES LTD. M2R51X116 December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ X ] Rule 13d-1 (b) [ ] Rule 13d-1 (c) [ ] Rule 13d-1 (d) *The remainder of this cover page shall be fill |
|
| January 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2022 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| January 5, 2022 |
Exhibit 99.1 1 Dea r Sha r e holder s, 2021 has been a pivotal and productive year for CollPlant which resulted in several significant achievements. With our unique and pioneering technology, resilient workforce and strong financial position, we have made meaningful progress in our business collaborations, products development, human assets and advancement of our strategy. I am happy to share with |
|
| December 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| December 2, 2021 |
Exhibit 99.1 CollPlant Announces Publication Highlighting its rhCollagen-based Photocurable Dermal Filler in the Plastic and Reconstructive Surgery Journal Preclinical modeling demonstrates potential for filler to enhance cell proliferation and new tissue regeneration for aesthetic medicine applications REHOVOT, Israel, December 2, 2021 /PRNewswire/ - CollPlant Biotechnologies (Nasdaq: CLGN), a re |
|
| November 18, 2021 |
Exhibit 99.1 CollPlant Biotechnologies Provides Business Updates and Third Quarter 2021 Financial Results Company launches rhCollagen-based BioInk platform with Collink.3DTM for use in 3D bioprinting of human tissues, scaffolds and organs Rehovot, Israel November 18, 2021 - CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies an |
|
| November 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| November 15, 2021 |
Exhibit 99.1 CollPlant Announces Commercial Launch of BioInk Platform with Collink.3DTM for Use in 3D Bioprinting of Human Tissues, Scaffolds and Organs rhCollagen-based BioInk provides biopharma and academia with attractive alternative to tissue extracted collagen for use in new product development REHOVOT, Israel, November 15, 2021 /PRNewswire/ - CollPlant Biotechnologies (Nasdaq: CLGN), a regen |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| October 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2021 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| October 12, 2021 |
Exhibit 99.1 CollPlant's rhCollagen BioInk Used by Technion Researchers to Develop 3D Bioprinted Vascularized Tissue Constructs REHOVOT, Israel, October 11th /PRNewswire/ - CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced that its recombinant huma |
|
| September 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2021 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| September 13, 2021 |
Exhibit 99.1 CollPlant Overview H.C. Wainwright 23 rd Annual Global Investment Conference Se p t ember 2021 Safe harbor statement Certain statements in this presentation constitute "forward - looking statements" within the meaning of Section 27 A of the Securities Act and Section 21 E of the Securities Exchange Act and are usually identified by the use of words such as "anticipates," "believes," " |
|
| September 9, 2021 |
Exhibit 99.1 CollPlant CEO Yehiel Tal elected to the Board of Directors of the International Society for Biofabrication (ISBF) REHOVOT, Israel, September 9, 2021/PRNewswire/ - CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced that Mr. Yehiel Tal, Chief Executive O |
|
| September 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2021 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| August 19, 2021 |
Exhibit 99.2 COLLPLANT BIOTECHNOLOGIES LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) AS OF JUNE 30, 2021 COLLPLANT BIOTECHNOLOGIES LTD. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) AS OF JUNE 30, 2021 TABLE OF CONTENTS Page CONDENSED CONSOLIDATED FINANCIAL STATEMENTS: Condensed Consolidated Balance Sheets F-2 - F-3 Condensed Consolidated Statements of Comprehensiv |
|
| August 19, 2021 |
Exhibit 99.1 CollPlant Biotechnologies Provides Business Updates and Second Quarter 2021 Financial Results Co-Develop Agreement with 3D Systems Highlights Expanding Commercial Collaborations Rehovot, Israel August 19, 2021, CollPlant (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today a |
|
| August 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| August 19, 2021 |
OPERATING AND FINANCIAL REVIEW AND PROSPECTS Exhibit 99.3 OPERATING AND FINANCIAL REVIEW AND PROSPECTS The following discussion and analysis should be read in conjunction with our consolidated financial statements and related notes included elsewhere in this Form 6-K and our Annual Report on Form 20-F for the year ended December 31, 2020 (the ?Annual Report?). Unless the context requires otherwise, the terms ?CollPlant,? ?we,? ?us,? ?our,? ? |
|
| August 19, 2021 |
CollPlant Appoints Medical Aesthetics Veteran Alisa Lask to Board of Directors Exhibit 99.4 CollPlant Appoints Medical Aesthetics Veteran Alisa Lask to Board of Directors Rehovot, Israel, August 19, 2021 ? CollPlant (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, announced the appointment of Alisa Lask to its Board of Directors. Ms. Lask is based in the United State |
|
| August 18, 2021 | ||
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 Commission File Number 001-38370 CollPlant Biotechnologies Ltd. |
|
| June 25, 2021 |
Exhibit 99.1 CollPlant Biotechnologies Ltd. 4 Oppenheimer St, Weizmann Science Park Rehovot 7670104, Israel NOTICE OF ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To be held on Wednesday, August 4, 2021 The annual and extraordinary general meeting of shareholders of CollPlant Biotechnologies Ltd. (the ?Company?) will be held at the offices of Gross & Co. at One Azrieli Center, Round Bu |
